Last reviewed · How we verify

Vraylar — Competitive Intelligence Brief

Vraylar (CARIPRAZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical Antipsychotic [EPC]. Area: Metabolic.

marketed Atypical Antipsychotic [EPC] D(3) dopamine receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Vraylar (CARIPRAZINE) — AbbVie. Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vraylar TARGET CARIPRAZINE AbbVie marketed Atypical Antipsychotic [EPC] D(3) dopamine receptor 2015-01-01
Pramipexole (Mirapex) Pramipexole (Mirapex) Massachusetts General Hospital marketed Dopamine agonist D2 dopamine receptor, D3 dopamine receptor
Lybalvi SAMIDORPHAN Alkermes Inc marketed Atypical Antipsychotic [EPC] Mu-type opioid receptor 2021-01-01
SAMIDORPHAN L-MALATE SAMIDORPHAN L-MALATE marketed Atypical Antipsychotic [EPC] dopamine and serotonin type 2 (5HT2) receptors, opioid receptors 2021-01-01
Caplyta LUMATEPERONE Intra-Cellular marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2019-01-01
Nuplazid PIMAVANSERIN Acadia Pharms Inc marketed Atypical Antipsychotic 5-hydroxytryptamine receptor 2A 2016-01-01
Rexulti BREXPIPRAZOLE Otsuka marketed Atypical Antipsychotic [EPC] D(2) dopamine receptor 2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Atypical Antipsychotic [EPC] class)

  1. · 2 drugs in this class
  2. AbbVie · 1 drug in this class
  3. Alkermes Inc · 1 drug in this class
  4. Eli Lilly · 1 drug in this class
  5. Hisamitsu · 1 drug in this class
  6. Intra-Cellular · 1 drug in this class
  7. Jazz Pharmaceuticals · 1 drug in this class
  8. Johnson & Johnson (Janssen) · 1 drug in this class
  9. Otsuka · 1 drug in this class
  10. Vanda Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vraylar — Competitive Intelligence Brief. https://druglandscape.com/ci/cariprazine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: